Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416474 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KMT2ALMNAGPR55PDE4A | |
| SCHEMBL26933211 | 0.81 | ALDH1A1 (0.38) | ALDH1A1KMT2ALMNAGPR55PDE4A | |
| SCHEMBL31728160 | 0.81 | ALDH1A1 (0.38) | ALDH1A1KMT2ALMNAGPR55PDE4A | |
| SCHEMBL28501805 | 0.81 | ALDH1A1 (0.37) | ALDH1A1KMT2ALMNAGPR55PDE4A | |
| SCHEMBL17142289 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2ALMNAKDM4EMAPT | |
| SCHEMBL2775914 | 0.76 | MAP4K4 (0.44) | ALDH1A1KDM4EMAPTABCB1ABCG2 | |
| SCHEMBL332545 | 0.76 | ABCB1 (0.38) | ABCB1ABCG2MKNK1 | |
| SCHEMBL856383 | 0.76 | PDE4A (0.48) | ALDH1A1KMT2ALMNAGPR55PDE4A | |
| SCHEMBL29460991 | 0.76 | PDE4A (0.48) | ALDH1A1KMT2ALMNAGPR55PDE4A | |
| SCHEMBL22220472 | 0.73 | ALDH1A1 (0.37) | ALDH1A1KMT2ALMNAGPR55PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3952902-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021225912-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-3761980-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-112135612-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020210404-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10793564-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
| WO-2019173653-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | ALDH1A1 3834/4885KMT2A 3326/4885LMNA 3365/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | ALDH1A1 3476/4885KMT2A 2821/4885LMNA 3407/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | ALDH1A1 3834/4885KMT2A 3326/4885LMNA 3365/4885 |
| US-10793564-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | ALDH1A1 3834/4885KMT2A 3326/4885LMNA 3365/4885 |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | ALDH1A1 3834/4885KMT2A 3326/4885LMNA 3365/4885 |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | ALDH1A1 3834/4885KMT2A 3326/4885LMNA 3365/4885 |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | ALDH1A1 3476/4885KMT2A 2821/4885LMNA 3407/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | ALDH1A1 3323/4885KMT2A 3704/4885LMNA 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.